Provectus Biopharmaceuticals Probability of Future OTC Stock Price Finishing Over 0.11
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus |
Provectus Biopharmaceutica Target Price Odds to finish over 0.11
The tendency of Provectus OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.11 | 90 days | 0.11 | about 98.0 |
Based on a normal probability distribution, the odds of Provectus Biopharmaceutica to move above the current price in 90 days from now is about 98.0 (This Provectus Biopharmaceuticals probability density function shows the probability of Provectus OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Provectus Biopharmaceutica has a beta of 0.45 indicating as returns on the market go up, Provectus Biopharmaceutica average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Provectus Biopharmaceuticals will be expected to be much smaller as well. Additionally Provectus Biopharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Provectus Biopharmaceutica Price Density |
| Price |
Predictive Modules for Provectus Biopharmaceutica
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Provectus Biopharmaceutica. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Provectus Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Provectus Biopharmaceutica Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Provectus Biopharmaceutica is not an exception. The market had few large corrections towards the Provectus Biopharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Provectus Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Provectus Biopharmaceutica within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.33 | |
β | Beta against Dow Jones | 0.45 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.06 |
Provectus Biopharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Provectus Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Provectus Biopharmaceutica can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Provectus Biopharmaceutica is not yet fully synchronised with the market data | |
| Provectus Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Provectus Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Provectus Biopharmaceuticals currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Provectus Biopharmaceuticals currently holds about 84.27 K in cash with (1.01 M) of positive cash flow from operations. |
Provectus Biopharmaceutica Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Provectus OTC Stock often depends not only on the future outlook of the current and potential Provectus Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Provectus Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 419.4 M |
Provectus Biopharmaceutica Technical Analysis
Provectus Biopharmaceutica's future price can be derived by breaking down and analyzing its technical indicators over time. Provectus OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Provectus Biopharmaceuticals. In general, you should focus on analyzing Provectus OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Provectus Biopharmaceutica Predictive Forecast Models
Provectus Biopharmaceutica's time-series forecasting models is one of many Provectus Biopharmaceutica's otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Provectus Biopharmaceutica's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Provectus Biopharmaceutica
Checking the ongoing alerts about Provectus Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Provectus Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Provectus Biopharmaceutica is not yet fully synchronised with the market data | |
| Provectus Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Provectus Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Provectus Biopharmaceuticals currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Provectus Biopharmaceuticals currently holds about 84.27 K in cash with (1.01 M) of positive cash flow from operations. |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |